Research Paper Volume 13, Issue 2 pp 1842—1858

Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma

Low DAPK1 expression correlates with tumor progression and metastasis in ccRCC patients. (A) DAPK1 mRNA expression in ccRCC (n=531) and adjacent normal kidney tissues (n=72) from the The Cancer Genome Atlas-Kidney Renal clear cell Carcinoma (TCGA-KIRC) database. (B) DAPK1 mRNA expression in paired ccRCC and para-cancerous kidney tissues (n=72) from the TCGA-KIRC database. (C) DAPK1 mRNA expression in primary (n=50) and metastatic ccRCC (n=20) tumors from the GSE43477 dataset. (D) DAPK1 mRNA expression in paired primary and metastatic ccRCC tumors (n=20) from the GSE43477 database. (E–I) Correlation between DAPK1 mRNA expression and clinicopathological parameters, including (E) T stage (T1-T4), (F) pathologic stage (I-IV), (G) tumor grade (G1-G4), (H) distant metastases, and (I) gender (male or female). Note: The data are shown as means ± SEM; ***p

Figure 1. Low DAPK1 expression correlates with tumor progression and metastasis in ccRCC patients. (A) DAPK1 mRNA expression in ccRCC (n=531) and adjacent normal kidney tissues (n=72) from the The Cancer Genome Atlas-Kidney Renal clear cell Carcinoma (TCGA-KIRC) database. (B) DAPK1 mRNA expression in paired ccRCC and para-cancerous kidney tissues (n=72) from the TCGA-KIRC database. (C) DAPK1 mRNA expression in primary (n=50) and metastatic ccRCC (n=20) tumors from the GSE43477 dataset. (D) DAPK1 mRNA expression in paired primary and metastatic ccRCC tumors (n=20) from the GSE43477 database. (EI) Correlation between DAPK1 mRNA expression and clinicopathological parameters, including (E) T stage (T1-T4), (F) pathologic stage (I-IV), (G) tumor grade (G1-G4), (H) distant metastases, and (I) gender (male or female). Note: The data are shown as means ± SEM; ***p<0.001, **p<0.01, *p<0.05.